NL-OMON28532
Not Yet Recruiting
N/A
Botulinum neurotoxin as new treatment modality in jerky psychogenic movement disorders: A randomized controlled trial.
Academic Medical CentreMeibergdreef 91105 AZ Amsterdam0 sites54 target enrollmentTBD
Conditionspsychogenic movement disorder
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- psychogenic movement disorder
- Sponsor
- Academic Medical CentreMeibergdreef 91105 AZ Amsterdam
- Enrollment
- 54
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eligible patients for the study have at least one consistent type of jerk of psychogenic origin. Two movement disorder specialists have to agree on the diagnosis based on clinical characteristics and on additional investigations if considered necessary. The diagnosis of psychogenic jerks needs to have a definite” or probable” level of certainty for psychogenic movement disorders. To be included, patients need to experience to be significantly impaired in daily functioning due to one specific jerk. The jerk of interest needs to be performed by a muscle or muscles amendable to injection and may be simple or complex if only treatment with BoNT is considered possible. No change in medication in the month prior to participation is allowed.
Exclusion Criteria
- •1\. Age \< 18 years or \> 80 years;
- •2\. Psychogenic jerk of interest present for \< 1 year;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
botulinum in childhood strabismusEye DiseasesSurgeryPaediatricschildhood strabismusPACTR201508001241218250
Not Yet Recruiting
N/A
Botulinum Neurotoxin (BoNT) as new treatment for functional (psychogenic) jerky movementdisorders.Botulinum neurotoxin (BoNT) has emerged as a useful therapy for several movement disorders associated with muscle overactivity such as dystonia and jerky movement disorders. At least 2–9% of patients seen in movement disorder clinics suffer from movement disorders with a psychogenic origin and a substantial part of them has jerks. These psychogenic jerky movement disorders cannot be accounted for by a known neurologic syndrome.NL-OMON26050Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 566911154
Active, Not Recruiting
N/A
Behandling med botulinumtoxin vid neurogen blåsfunktionsstörningThe trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy.EUCTR2005-003068-47-SERegion Skåne, Universitetssjukhuset i Lund, Urologiska kliniken40
Completed
Phase 2
Botulinum toxin as a new treatment modality for jerky psychogenic movement disorders: a monocenter randomized controlled trialconversion disorderfunctional movement disorder10028037NL-OMON34213Academisch Medisch Centrum50
Completed
Phase 4
Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact InsoleHallux ValgusNCT01501500Chang Gung Memorial Hospital25